Advances in hemorrhagic stroke therapy: conventional and novel approaches (Q36944012)

17 August 2017

1 reference

title

Advances in hemorrhagic stroke therapy: conventional and novel approaches (English)

1 reference

17 August 2017

Paul A Lapchak

1

1 reference

PubMed ID

17874968

17 August 2017

Dalia M Araujo

series ordinal

2

1 reference

PubMed ID

17874968

17 August 2017

language of work or name

English

0 references

publication date

1 September 2007

1 reference

Expert Opinion on Emerging Drugs

17 August 2017

1 reference

17 August 2017

12

1 reference

17 August 2017

3

1 reference

17 August 2017

389-406

1 reference

Racial variations in location and risk of intracerebral hemorrhage

17 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Trends in hospitalization rate, hospital case fatality, and mortality rate of stroke by subtype in Minneapolis-St. Paul, 1980-2002.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Hemorrhagic transformation following ischemic stroke: significance, causes, and relationship to therapy and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Recent advances in the management of acute intracerebral hemorrhage

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

21 January 2018

Subarachnoid haemorrhage

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Hemorrhagic transformation in cardioembolic cerebral infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Hemorrhagic transformation of brain infarct: predictability in the first 5 hours from stroke onset and influence on clinical outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Clinical interpretation and use of stroke scales

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Factor analysis of the National Institutes of Health Stroke Scale in patients with large strokes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

NIHSS training and certification using a new digital video disk is reliable

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

A modified National Institutes of Health Stroke Scale for use in stroke clinical trials: preliminary reliability and validity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Course, management and outcome of oral-anticoagulant-related intracranial haemorrhages

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

The increasing incidence of anticoagulant-associated intracerebral hemorrhage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Intracranial hemorrhage associated with revascularization therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Tissue plasminogen activator for acute ischemic stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

tPA in acute ischemic stroke: United States experience and issues for the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Development of thrombolytic therapy for stroke: a perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Reliability assessment of computerized tomography scanning measurements in intracerebral hematoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Treatment of intracerebral haemorrhage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Cohort study of intraventricular thrombolysis with recombinant tissue plasminogen activator for aneurysmal intraventricular hemorrhage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Effect of recombinant tissue plasminogen activator on clot lysis and ventricular dilatation in the treatment of severe intraventricular haemorrhage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Prospective studies in patients with intraventricular haemorrhage without the capacity to give consent in Germany--a legal dilemma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Intraventricular thrombolysis speeds blood clot resolution: results of a pilot, prospective, randomized, double-blind, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Is emergent anti-hypertensive treatment beneficial in intracranial hemorrhage?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Treatment of acute hypertension in patients with intracerebral hemorrhage using American Heart Association guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Dynamics of intraventricular hemorrhage in patients with spontaneous intracerebral hemorrhage: risk factors, clinical impact, and effect of hemostatic therapy with recombinant activated factor VII.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Seminal hemostatic factors: then and now.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Treatment of factor VIII inhibitors: products and strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Off-label use of recombinant factor VIIa in patients following bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Recombinant factor VIIa used to control massive haemorrhage during renal transplantation surgery; vascular graft remained patent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

The use of recombinant factor VIIa in the treatment of bleeding disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

New insights into the coagulation system and implications for new therapeutic options with recombinant factor VIIa

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Thromboembolic adverse events after use of recombinant human coagulation factor VIIa

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Safety and feasibility of recombinant factor VIIa for acute intracerebral hemorrhage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Recombinant activated factor VII for acute intracerebral hemorrhage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Localization of electrodes in the subthalamic nucleus on magnetic resonance imaging.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Albumin treatment reduces neurological deficit and protects blood-brain barrier integrity after acute intracortical hematoma in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Experimental intracerebral hemorrhage in the mouse: histological, behavioral, and hemodynamic characterization of a double-injection model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Nimodipine treatment to assess a modified mouse model of intracerebral hemorrhage

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Neurovascular proteases in brain injury, hemorrhage and remodeling after stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

A new experimental model in rats for study of the pathophysiology of subarachnoid hemorrhage

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

High dose baclofen is neuroprotective but also causes intracerebral hemorrhage: a quantal bioassay study using the intraluminal suture occlusion method

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Effect of ganaxolone in a rodent model of cerebral hematoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Matrix metalloproteinase expression increases after cerebral focal ischemia in rats: inhibition of matrix metalloproteinase-9 reduces infarct size

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Matrix metalloproteinases in brain injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Metalloproteinase inhibition blocks edema in intracerebral hemorrhage in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Neuroprotection by inhibition of matrix metalloproteinases in a mouse model of intracerebral haemorrhage

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Delayed argatroban treatment reduces edema in a rat model of intracerebral hemorrhage

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Reducing bleeding complications after thrombolytic therapy for stroke: clinical potential of metalloproteinase inhibitors and spin trap agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Effects of the spin trap agent disodium- [tert-butylimino)methyl]benzene-1,3-disulfonate N-oxide (generic NXY-059) on intracerebral hemorrhage in a rabbit Large clot embolic stroke model: combination studies with tissue plasminogen activator

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

The nonpeptide glycoprotein IIb/IIIa platelet receptor antagonist SM-20302 reduces tissue plasminogen activator-induced intracerebral hemorrhage after thromboembolic stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Metalloproteinase inhibition reduces thrombolytic (tissue plasminogen activator)-induced hemorrhage after thromboembolic stroke.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Intracerebral hemorrhage after experimental embolic infarction. Anticoagulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Acute hypertension, but not thrombolysis, increases the incidence and severity of hemorrhagic transformation following experimental stroke in rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Inflammatory gene expression in cerebral ischemia and trauma. Potential new therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Matrix metalloproteinases in cerebrovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Glutamate and the pathophysiology of hypoxic--ischemic brain damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Mechanisms of secondary brain damage in global and focal ischemia: a speculative synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Memantine in moderate-to-severe Alzheimer disease evidence and ethics based?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Memantine displaces [3H]MK-801 at therapeutic concentrations in postmortem human frontal cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist--a review of preclinical data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Patch clamp studies on the kinetics and selectivity of N-methyl-D-aspartate receptor antagonism by memantine (1-amino-3,5-dimethyladamantan).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Effects of memantine and MK-801 on NMDA-induced currents in cultured neurones and on synaptic transmission and LTP in area CA1 of rat hippocampal slices

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Memantine, an uncompetitive low affinity NMDA open-channel antagonist improves clinical rating scores in a multiple infarct embolic stroke model in rabbits.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Neuroprotective concentrations of the N-methyl-D-aspartate open-channel blocker memantine are effective without cytoplasmic vacuolation following post-ischemic administration and do not block maze learning or long-term potentiation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Neuroprotection by the NMDA receptor-associated open-channel blocker memantine in a photothrombotic model of cerebral focal ischemia in neonatal rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Protective effects of memantine against ischemia-reperfusion injury in spontaneously hypertensive rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Neuroprotection by memantine, a non-competitive NMDA receptor antagonist after traumatic brain injury in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Galantamine and memantine produce different degrees of neuroprotection in rat hippocampal slices subjected to oxygen-glucose deprivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Memantine reduces hematoma expansion in experimental intracerebral hemorrhage, resulting in functional improvement

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Combined neuroprotective effects of celecoxib and memantine in experimental intracerebral hemorrhage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Regulation of tumour necrosis factor-alpha processing by a metalloproteinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Relaxed specificity of matrix metalloproteinases (MMPS) and TIMP insensitivity of tumor necrosis factor-alpha (TNF-alpha) production suggest the major TNF-alpha converting enzyme is not an MMP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Immunohistochemistry of matrix metalloproteinases in reperfusion injury to rat brain: activation of MMP-9 linked to stromelysin-1 and microglia in cell cultures.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Modulation of airway remodeling-associated mediators by the antifibrotic compound, pirfenidone, and the matrix metalloproteinase inhibitor, batimastat, during acute lung injury in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Regulation of matrix metalloproteinases and effect of MMP-inhibition in heart transplant related reperfusion injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Batimastat reduces Mycobacterium tuberculosis-induced apoptosis in macrophages.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

(E)-2(R)-[1(S)-(Hydroxycarbamoyl)-4-phenyl-3-butenyl]-2'-isobutyl-2'-(methanesulfonyl)-4-methylvalerohydrazide (Ro 32-7315), a selective and orally active inhibitor of tumor necrosis factor-alpha convertase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Inhibition of tumor necrosis factor-alpha-converting enzyme by a selective antagonist protects brain from focal ischemic injury in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Matrix metalloproteinases increase very early during experimental focal cerebral ischemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Role for matrix metalloproteinase 9 after focal cerebral ischemia: effects of gene knockout and enzyme inhibition with BB-94.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Role of matrix metalloproteinases in delayed neuronal damage after transient global cerebral ischemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Involvement of matrix metalloproteinase in thrombolysis-associated hemorrhagic transformation after embolic focal ischemia in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Extracellular proteolysis in brain injury and inflammation: role for plasminogen activators and matrix metalloproteinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Cerebral ischemia, matrix metalloproteinases, and TNF-alpha: MMP inhibitors may act not exclusively by reducing MMP activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Closure of the blood-brain barrier by matrix metalloproteinase inhibition reduces rtPA-mediated mortality in cerebral ischemia with delayed reperfusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Profiles of matrix metalloproteinases, their inhibitors, and laminin in stroke patients: influence of different therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Identification of a serum gelatinase associated with the occurrence of cerebral aneurysms as pro-matrix metalloproteinase-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Expression of matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinase (TIMP) in cerebral cavernous malformations: immunohistochemical analysis of MMP-2, -9 and TIMP-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Free radicals as mediators of neuronal injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Antioxidants, oxidative stress, and degenerative neurological disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Involvement of free radicals in cerebral vascular reperfusion injury evaluated in a transient focal cerebral ischemia model of rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Potential markers of oxidative stress in stroke.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Diagnostic and therapeutic applications of azulenyl nitrone spin traps

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Characterization of the radical trapping activity of a novel series of cyclic nitrone spin traps

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Excretion, metabolism and tissue distribution of a spin trapping agent, alpha-phenyl-N-tert-butyl-nitrone (PBN) in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Neuroprotective effects of phenyl-t-butyl-nitrone in gerbil global brain ischemia and in cultured rat cerebellar neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

N-tert-butyl-alpha-phenylnitrone improves recovery of brain energy state in rats following transient focal ischemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Stilbazulenyl nitrone (STAZN): a nitronyl-substituted hydrocarbon with the potency of classical phenolic chain-breaking antioxidants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Comparison of the radical trapping ability of PBN, S-PPBN and NXY-059.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Neuroprotective effects of the spin trap agent disodium-[(tert-butylimino)methyl]benzene-1,3-disulfonate N-oxide (generic NXY-059) in a rabbit small clot embolic stroke model: combination studies with the thrombolytic tissue plasminogen activator

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Efficacy of disodium 4-[(tert-butylimino)methyl]benzene-1,3-disulfonate N-oxide (NXY-059), a free radical trapping agent, in a rat model of hemorrhagic stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

NXY-059 does not affect bleeding time in healthy volunteers: a randomized, double-blind, placebo-controlled, 3-period crossover phase I study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Effect of a novel free radical scavenger, edaravone (MCI-186), on acute brain infarction. Randomized, placebo-controlled, double-blind study at multicenters

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Neuroprotective effects of edaravone: a novel free radical scavenger in cerebrovascular injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Edaravone, a novel radical scavenger, inhibits oxidative modification of low-density lipoprotein (LDL) and reverses oxidized LDL-mediated reduction in the expression of endothelial nitric oxide synthase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Molecular basis of the diagnosis and treatment of polycythemia vera and essential thrombocythemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Erythropoietin biology in cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

The role of erythropoietin therapy in the critically ill.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Epoetin alfa versus darbepoetin alfa in chemotherapy-related anemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Recombinant human erythropoietin in the treatment of nonrenal anemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Turning cells red: signal transduction mediated by erythropoietin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Novel applications of recombinant erythropoietin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Erythropoietin: a novel neuroprotective cytokine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Erythropoietin: novel approaches to neuroprotection in human brain disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Neuroprotection in brain and spinal cord trauma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Erythropoietin and the nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Neuroprotection in the PNS: erythropoietin and immunophilin ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Strategies to promote neural repair and regeneration after spinal cord injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Erythropoietin and neuroprotection: a therapeutic perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Neuroprotection targets after traumatic brain injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Thromboembolic events in patients with myelodysplastic syndrome receiving thalidomide in combination with darbepoietin-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Carbamylated erythropoietin ameliorates the metabolic stress induced in vivo by severe chronic hypoxia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Reduced functional deficits, neuroinflammation, and secondary tissue damage after treatment of stroke by nonerythropoietic erythropoietin derivatives.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Erythropoietin reduces perihematomal inflammation and cell death with eNOS and STAT3 activations in experimental intracerebral hemorrhage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Granulocyte colony-stimulating factor induces sensorimotor recovery in intracerebral hemorrhage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Statin safety: an overview and assessment of the data--2005.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Beyond the laboratory: clinical implications for statin pleiotropy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Statins and ischemic stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

HMG CoA reductase inhibitors (statins): use in stroke prevention and outcome after stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Lipids and stroke: the opportunity of lipid-lowering treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

The pleiotropic effects of HMG-CoA reductase inhibitors: their role in osteoporosis and dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Pleiotropic effects of HMG-CoA reductase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Vascular effects of statins in stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Statins: potential new indications in inflammatory conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Clinical trials of neuroprotective therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Improvement in neurological outcome after administration of atorvastatin following experimental intracerebral hemorrhage in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

HMG-CoA reductase inhibitor, atorvastatin, promotes sensorimotor recovery, suppressing acute inflammatory reaction after experimental intracerebral hemorrhage

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Protein kinase activity associated with the avian sarcoma virus src gene product

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Src kinase becomes preferentially associated with the VEGFR, KDR/Flk-1, following VEGF stimulation of vascular endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Signaling pathways for early brain injury after subarachnoid hemorrhage

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Dynamic platelet accumulation at the site of the occluded middle cerebral artery and in downstream microvessels is associated with loss of microvascular integrity after embolic middle cerebral artery occlusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Proteasomal inhibition in intracerebral hemorrhage: neuroprotective and anti-inflammatory effects of bortezomib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Lysophosphatidylcholine-induced myocardial damage is inhibited by pretreatment with poloxamer 188 in isolated rat heart.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Human neural stem cells over-expressing VEGF provide neuroprotection, angiogenesis and functional recovery in mouse stroke model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Brain genomics of intracerebral hemorrhage

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Advances in ischemic stroke treatment: neuroprotective and combination therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

Processing of tumour necrosis factor-α precursor by metalloproteinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.389

10.1517/14728214.12.3.389

21 January 2018

Identifiers

DOI

1 reference

17 August 2017

1 reference

PubMed ID

17874968